Developer docs
API playgroundTry for free, no card

Search company profiles

Optoceutics

Full company profile

uuid0004rnl

Namestring
Optoceutics
Legal namestring
Optoceutics
Websiteurl
optoceutics.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Optoceutics is a privately held consumer wellness company founded in 2018 that develops and sells the EVY LIGHT device, a non-invasive 40Hz light and sound stimulation product marketed to families and caregivers of individuals with Alzheimer's disease, dementia, and Mild Cognitive Impairment (MCI). The technology is grounded in gamma wave entrainment: 40Hz light is delivered via the hardware device and 40Hz sound is delivered through the optional EVY INSIGHT mobile app (iOS and Android), producing a dual-pathway multi-sensory stimulation protocol. A key proprietary element is the patented Invisible Spectral Flicker (ISF) technology, which reduces the perceived flicker of 40Hz strobe light and enables use during everyday activities such as reading, watching TV, or conversing. The product is positioned as an FDA low-risk general wellness device and is not subject to FDA medical-device regulation.

The company was co-developed with UC Berkeley and the Technical University of Denmark (DTU) and is supported by a scientific advisory board that includes prominent Alzheimer's researchers. Optoceutics sells EVY LIGHT directly to consumers through its optoceutics.com storefront with a 90-day money-back guarantee and free shipping, and has launched a healthcare provider program targeting clinicians who serve dementia patients. Revenue mechanics are anchored on one-time hardware device sales, with the EVY INSIGHT app potentially layered as a recurring software component (pricing is not publicly disclosed).

The company is headquartered in Berkeley, California, with operational ties to Kongens Lyngby, Denmark, and reports 11-50 employees. Disclosed external capital is limited to approximately $82K raised in 2019 from EISMEA and SkyDeck Berkeley, and no subsequent funding rounds, mergers, acquisitions, or leadership changes have been disclosed in the available source data.

Short descriptiontext

Optoceutics develops and sells EVY LIGHT, a patented 40Hz light and sound stimulation device marketed to families and caregivers of patients with Alzheimer's, dementia, and Mild Cognitive Impairment. It is sold direct-to-consumer via optoceutics.com with an optional mobile app.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBerkeley, United States
HQ citystring
Berkeley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
40Hz light therapy, brain wellness devices, gamma wave stimulation, Alzheimer's wellness products, cognitive health technology
Industry2 codes
PRIMARYCRACAQAL
Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHSABAEAH
Cognitive Stimulation & Reminiscence Therapy (Non-Clinical)
Home & Personal Services/Elder Care & In-Home Care Services/Dementia & Alzheimer’s In-Home Care
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Brain Wellness Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1EVY LIGHT Device Sales
TypeOne Time License
Description

Sale of the EVY LIGHT hardware device, a brain wellness device that delivers 40Hz light stimulation. The device is sold directly through the company's e-commerce platform with a 90-day money-back guarantee.

optoceutics.com
2EVY INSIGHT App (Optional)
TypeSubscription Recurring
Description

The companion mobile app provides 40Hz sound stimulation, brightness customization, and usage tracking. The app is optional and available for Apple and Android devices, potentially offered as an add-on or included with device purchase.

optoceutics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1EVY
Description

General wellness device using 40Hz light and sound stimulation for brain health, targeting families living with Alzheimer's, dementia, and Mild Cognitive Impairment (MCI)

optoceutics.com
+2 more records
Core offering1 text field

Optoceutics sells the EVY LIGHT, a consumer-grade brain wellness device that delivers 40Hz light stimulation using patented Invisible Spectral Flicker (ISF) technology, complemented by the optional EVY INSIGHT mobile app that adds 40Hz sound therapy, brightness control, and usage tracking. The product is sold directly to consumers (primarily families and caregivers of individuals with Alzheimer's, dementia, or MCI) through the company's e-commerce storefront with a 90-day money-back guarantee.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 95% of families report improvements in sleep, memory, focus, energy, and mood within 5 weeks
+4 more records
Product overview1 text field

Optoceutics offers a unified consumer wellness solution centered on the EVY LIGHT device — a 40Hz light stimulation device featuring patented Invisible Spectral Flicker (ISF) technology — complemented by the EVY INSIGHT mobile app (iOS and Android) which adds app-based 40Hz sound stimulation, brightness control, and usage tracking. The company operates a direct-to-consumer model with a 90-day money-back guarantee and serves individuals with Alzheimer's, dementia, and Mild Cognitive Impairment (MCI) as a general wellness product (not a medical device).

Product and service2 records
1EVY LIGHT
CategoryBrain Wellness Device
Description

EVY LIGHT is a general wellness hardware device that delivers 40Hz light stimulation using patented Invisible Spectral Flicker (ISF) technology to support cognitive health in individuals living with Alzheimer's, dementia, or Mild Cognitive Impairment (MCI). It is sold directly to families and caregivers through the company's e-commerce site with one-button simple operation.

2EVY INSIGHT App
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

EVY was developed in collaboration with UC Berkeley. The university partnership provides scientific credibility and research infrastructure for the 40Hz light therapy technology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

EVY was developed in collaboration with DTU (Danish Technical University). The international academic partnership contributed to the research and development of the 40Hz therapy technology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Masonicare, a senior living and memory care community, conducted a 6-week independent pilot study of EVY. Results showed caregivers saw residents improve across all five tracked areas: sleep, mood, focus, energy, and memory, and caregivers reported the device eased their daily workload. Published as a white paper.

4Scientific Advisory Board
Strategic tierCoreTypeOthers
Description

The scientific advisory board includes Dr. Jeffrey Cummings (Prof., MD, ScD, Neurology), Dr. Henrik Zetterberg (Prof., MD, Neurochemist), Dr. William Jagust (Prof., MD, Alzheimer's Expert), Dr. Silke Kern (Prof., PhD, MD), and Dr. Jan Pedersen (Biophysicist, PhD, MSc). These advisors ensure EVY is backed by the latest cognitive health research.

optoceutics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Alzheimer's Association
TypeOthers
Description

The Alzheimer's Association is the dominant US patient advocacy, research funding, and provider-credentialing body for Alzheimer's care. While not a commercial peer, it shapes the recommendation channels and clinical credibility that Optoceutics' provider program depends on.

TypeBroad incumbent
Description

Cala Health markets FDA-cleared wearable neuromodulation therapy (TAPS) for essential tremor and is expanding into other neurological indications. It represents a broader incumbent in wearable neurostimulation with regulatory and reimbursement muscle Optoceutics lacks.

TypeEmerging player
Description

Cognivue develops FDA-cleared computerized cognitive assessment tools used in primary care to detect early cognitive decline. It is comparable to Optoceutics as an enabler in the early-detection and management pathway for Alzheimer's and MCI patients, though in diagnostics rather than therapy.

4Neuronix
TypeDirect peer
Description

Neuronix develops neurostimulation-based therapies (neuroAD) for Alzheimer's disease, combining transcranial magnetic stimulation with cognitive training. It competes with Optoceutics in the non-pharmacological Alzheimer's intervention space, though via a different stimulation modality.

5Cognito Therapeutics
TypeDirect peer
Description

Cognito Therapeutics is developing a 40Hz non-invasive neuromodulation therapy for Alzheimer's disease — the same core modality Optoceutics commercializes via EVY LIGHT. Cognito is running the landmark HOPE trial that supplies the headline efficacy figures Optoceutics cites, making it the most direct clinical and competitive peer.

TypeBroad incumbent
Description

NeuroPace commercializes the FDA-approved RNS system for epilepsy, a brain neuromodulation platform. It is a broader incumbent in implanted/responsive neurostimulation relevant to Optoceutics' long-term aspiration of clinical-grade brain stimulation.

TypeDirect peer
Description

Vielight sells consumer and clinical photobiomodulation (PBM) devices that deliver intranasal and transcranial light stimulation, including 40Hz-capable models. It overlaps Optoceutics on light-based neuromodulation for brain health, with a similar direct-to-consumer wellness positioning.

TypeEmerging player
Description

LumosTech (formerly Axon Labs) is developing light-based cognitive therapy devices targeting cognitive impairment and circadian rhythm disorders. It is comparable to Optoceutics as a light-modality neurostimulation startup addressing adjacent cognitive and sleep indications.

9BrainBright
TypeEmerging player
Description

BrainBright is a Nordic startup offering light/sound-based brain stimulation devices for cognitive performance and dementia support. It is comparable to Optoceutics on 40Hz-style consumer neurostimulation and geographically close (Nordics) to Optoceutics' Danish roots.

TypeEmerging player
Description

Posit Science sells BrainHQ, a cognitive training software platform targeting healthy aging and dementia risk reduction. It overlaps Optoceutics on the non-pharmacological cognitive-wellness value proposition, with a software-first, recurring-revenue model that contrasts Optoceutics' hardware approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Optoceutics

Brain Wellness Devicesoptoceutics.com

Optoceutics develops and sells EVY LIGHT, a patented 40Hz light and sound stimulation device marketed to families and caregivers of patients with Alzheimer's, dementia, and Mild Cognitive Impairment. It is sold direct-to-consumer via optoceutics.com with an optional mobile app.

What Optoceutics does

Optoceutics is a privately held consumer wellness company founded in 2018 that develops and sells the EVY LIGHT device, a non-invasive 40Hz light and sound stimulation product marketed to families and caregivers of individuals with Alzheimer's disease, dementia, and Mild Cognitive Impairment (MCI). The technology is grounded in gamma wave entrainment: 40Hz light is delivered via the hardware device and 40Hz sound is delivered through the optional EVY INSIGHT mobile app (iOS and Android), producing a dual-pathway multi-sensory stimulation protocol. A key proprietary element is the patented Invisible Spectral Flicker (ISF) technology, which reduces the perceived flicker of 40Hz strobe light and enables use during everyday activities such as reading, watching TV, or conversing. The product is positioned as an FDA low-risk general wellness device and is not subject to FDA medical-device regulation.

The company was co-developed with UC Berkeley and the Technical University of Denmark (DTU) and is supported by a scientific advisory board that includes prominent Alzheimer's researchers. Optoceutics sells EVY LIGHT directly to consumers through its optoceutics.com storefront with a 90-day money-back guarantee and free shipping, and has launched a healthcare provider program targeting clinicians who serve dementia patients. Revenue mechanics are anchored on one-time hardware device sales, with the EVY INSIGHT app potentially layered as a recurring software component (pricing is not publicly disclosed).

The company is headquartered in Berkeley, California, with operational ties to Kongens Lyngby, Denmark, and reports 11-50 employees. Disclosed external capital is limited to approximately $82K raised in 2019 from EISMEA and SkyDeck Berkeley, and no subsequent funding rounds, mergers, acquisitions, or leadership changes have been disclosed in the available source data.

Optoceutics firmographics

Firmographics
Name
Optoceutics
Legal name
Optoceutics
Website
https://optoceutics.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Optoceutics develops and sells EVY LIGHT, a patented 40Hz light and sound stimulation device marketed to families and caregivers of patients with Alzheimer's, dementia, and Mild Cognitive Impairment. It is sold direct-to-consumer via optoceutics.com with an optional mobile app.
Ownership category
akta.pro rank

Optoceutics industry classification

Industry
Product category
Brain Wellness Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYCRACAQAL
Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHSABAEAH
Cognitive Stimulation & Reminiscence Therapy (Non-Clinical)
Home & Personal Services/Elder Care & In-Home Care Services/Dementia & Alzheimer’s In-Home Care

Keywords

  • 40Hz light therapy
  • Brain wellness devices
  • Gamma wave stimulation
  • Alzheimer's wellness products
  • Cognitive health technology

Where Optoceutics is headquartered

Location

Headquarters

HQ city
Berkeley
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Optoceutics business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. EVY LIGHT Device Sales: Sale of the EVY LIGHT hardware device, a brain wellness device that delivers 40Hz light stimulation. The device is sold directly through the company's e-commerce platform with a 90-day money-back guarantee.
  2. EVY INSIGHT App (Optional): The companion mobile app provides 40Hz sound stimulation, brightness customization, and usage tracking. The app is optional and available for Apple and Android devices, potentially offered as an add-on or included with device purchase.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Optoceutics product offering

Product offering

Core offering

Optoceutics sells the EVY LIGHT, a consumer-grade brain wellness device that delivers 40Hz light stimulation using patented Invisible Spectral Flicker (ISF) technology, complemented by the optional EVY INSIGHT mobile app that adds 40Hz sound therapy, brightness control, and usage tracking. The product is sold directly to consumers (primarily families and caregivers of individuals with Alzheimer's, dementia, or MCI) through the company's e-commerce storefront with a 90-day money-back guarantee.

Product overview

Optoceutics offers a unified consumer wellness solution centered on the EVY LIGHT device — a 40Hz light stimulation device featuring patented Invisible Spectral Flicker (ISF) technology — complemented by the EVY INSIGHT mobile app (iOS and Android) which adds app-based 40Hz sound stimulation, brightness control, and usage tracking. The company operates a direct-to-consumer model with a 90-day money-back guarantee and serves individuals with Alzheimer's, dementia, and Mild Cognitive Impairment (MCI) as a general wellness product (not a medical device).

Differentiator

Problem solved

Functional benefit

Brands

  • EVY: General wellness device using 40Hz light and sound stimulation for brain health, targeting families living with Alzheimer's, dementia, and Mild Cognitive Impairment (MCI)
  • EVY LIGHT
  • EVY INSIGHT

Products and services

  • EVY LIGHT EVY LIGHT is a general wellness hardware device that delivers 40Hz light stimulation using patented Invisible Spectral Flicker (ISF) technology to support cognitive health in individuals living with Alzheimer's, dementia, or Mild Cognitive Impairment (MCI). It is sold directly to families and caregivers through the company's e-commerce site with one-button simple operation.
  • EVY INSIGHT App

Quantifiable outcome

  • 95% of families report improvements in sleep, memory, focus, energy, and mood within 5 weeks
  • +4 more outcomes

Companies that use Optoceutics

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Optoceutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability3 records

Feature4 records

Optoceutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • University of California, BerkeleycoreStrategic or Co-development PartnerEVY was developed in collaboration with UC Berkeley. The university partnership provides scientific credibility and research infrastructure for the 40Hz light therapy technology.
  • Technical University of Denmark (DTU)coreStrategic or Co-development PartnerEVY was developed in collaboration with DTU (Danish Technical University). The international academic partnership contributed to the research and development of the 40Hz therapy technology.
  • MasonicareminorStrategic or Co-development PartnerMasonicare, a senior living and memory care community, conducted a 6-week independent pilot study of EVY. Results showed caregivers saw residents improve across all five tracked areas: sleep, mood, focus, energy, and memory, and caregivers reported the device eased their daily workload. Published as a white paper.
  • Scientific Advisory BoardcoreOthersThe scientific advisory board includes Dr. Jeffrey Cummings (Prof., MD, ScD, Neurology), Dr. Henrik Zetterberg (Prof., MD, Neurochemist), Dr. William Jagust (Prof., MD, Alzheimer's Expert), Dr. Silke Kern (Prof., PhD, MD), and Dr. Jan Pedersen (Biophysicist, PhD, MSc). These advisors ensure EVY is backed by the latest cognitive health research.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Optoceutics competitors and assessment

Company assessment

Others

  • Alzheimer's Association: The Alzheimer's Association is the dominant US patient advocacy, research funding, and provider-credentialing body for Alzheimer's care. While not a commercial peer, it shapes the recommendation channels and clinical credibility that Optoceutics' provider program depends on.

Broad incumbents

  • Cala Health: Cala Health markets FDA-cleared wearable neuromodulation therapy (TAPS) for essential tremor and is expanding into other neurological indications. It represents a broader incumbent in wearable neurostimulation with regulatory and reimbursement muscle Optoceutics lacks.
  • NeuroPace: NeuroPace commercializes the FDA-approved RNS system for epilepsy, a brain neuromodulation platform. It is a broader incumbent in implanted/responsive neurostimulation relevant to Optoceutics' long-term aspiration of clinical-grade brain stimulation.

Emerging players

  • Cognivue: Cognivue develops FDA-cleared computerized cognitive assessment tools used in primary care to detect early cognitive decline. It is comparable to Optoceutics as an enabler in the early-detection and management pathway for Alzheimer's and MCI patients, though in diagnostics rather than therapy.
  • LumosTech: LumosTech (formerly Axon Labs) is developing light-based cognitive therapy devices targeting cognitive impairment and circadian rhythm disorders. It is comparable to Optoceutics as a light-modality neurostimulation startup addressing adjacent cognitive and sleep indications.
  • BrainBright: BrainBright is a Nordic startup offering light/sound-based brain stimulation devices for cognitive performance and dementia support. It is comparable to Optoceutics on 40Hz-style consumer neurostimulation and geographically close (Nordics) to Optoceutics' Danish roots.
  • Posit Science (BrainHQ): Posit Science sells BrainHQ, a cognitive training software platform targeting healthy aging and dementia risk reduction. It overlaps Optoceutics on the non-pharmacological cognitive-wellness value proposition, with a software-first, recurring-revenue model that contrasts Optoceutics' hardware approach.

Direct peers

  • Neuronix: Neuronix develops neurostimulation-based therapies (neuroAD) for Alzheimer's disease, combining transcranial magnetic stimulation with cognitive training. It competes with Optoceutics in the non-pharmacological Alzheimer's intervention space, though via a different stimulation modality.
  • Cognito Therapeutics: Cognito Therapeutics is developing a 40Hz non-invasive neuromodulation therapy for Alzheimer's disease — the same core modality Optoceutics commercializes via EVY LIGHT. Cognito is running the landmark HOPE trial that supplies the headline efficacy figures Optoceutics cites, making it the most direct clinical and competitive peer.
  • Vielight: Vielight sells consumer and clinical photobiomodulation (PBM) devices that deliver intranasal and transcranial light stimulation, including 40Hz-capable models. It overlaps Optoceutics on light-based neuromodulation for brain health, with a similar direct-to-consumer wellness positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Optoceutics social profiles

Digital presence

Optoceutics compliance and trust

Trust signal

Compliance1 record

Optoceutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Optoceutics leadership team

Management profile

Number of profiles

Profiles2 records

Optoceutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Optoceutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Optoceutics

What does Optoceutics do?

Optoceutics sells the EVY LIGHT, a consumer-grade brain wellness device that delivers 40Hz light stimulation using patented Invisible Spectral Flicker (ISF) technology, complemented by the optional EVY INSIGHT mobile app that adds 40Hz sound therapy, brightness control, and usage tracking. The product is sold directly to consumers (primarily families and caregivers of individuals with Alzheimer's, dementia, or MCI) through the company's e-commerce storefront with a 90-day money-back guarantee.

Is Optoceutics a public or private company?

Optoceutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Optoceutics founded?

Optoceutics was founded in 2018. It employs 11 to 50 people.

Where is Optoceutics based?

Optoceutics is headquartered in Berkeley, United States, in the North America region.

How does Optoceutics make money?

Two revenue lines are on record. EVY LIGHT Device Sales are the primary driver. The others are EVY INSIGHT App (Optional).

Who are Optoceutics's main competitors?

Alzheimer's Association is listed as an others. Broad incumbents are Cala Health and NeuroPace. Emerging players are Cognivue, LumosTech, BrainBright and Posit Science (BrainHQ). Direct peers are Neuronix, Cognito Therapeutics and Vielight.

Does Optoceutics have an API?

No public API is recorded for Optoceutics.

What industry is Optoceutics in?

Optoceutics's product category is Brain Wellness Devices. Its primary akta.pro industry code is CRACAQAL, Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices), with a secondary code of HSABAEAH, Cognitive Stimulation & Reminiscence Therapy (Non-Clinical). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales